Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia
Jason Y Park, Xi Zhang, Nathalie Nguyen, Rhonda F Souza, Stuart J Spechler, Edaire Cheng, Jason Y Park, Xi Zhang, Nathalie Nguyen, Rhonda F Souza, Stuart J Spechler, Edaire Cheng
Abstract
Objective: Besides reducing gastric acid secretion, proton pump inhibitors (PPIs) suppress Th2-cytokine-stimulated expression of an eosinophil chemoattractant (eotaxin-3) by esophageal epithelial cells through acid-independent, anti-inflammatory mechanisms. To explore acid-inhibitory and acid-independent, anti-inflammatory PPI effects in reducing esophageal eosinophilia, we studied eotaxin-3 expression by the proximal and distal esophagus of children with esophageal eosinophilia before and after PPI therapy. In vitro, we studied acid and bile salt effects on IL-13-stimulated eotaxin-3 expression by esophageal epithelial cells.
Design: Among 264 children with esophageal eosinophilia seen at a tertiary pediatric hospital from 2008 through 2012, we identified 10 with esophageal biopsies before and after PPI treatment alone. We correlated epithelial cell eotaxin-3 immunostaining with eosinophil numbers in those biopsies. In vitro, we measured eotaxin-3 protein secretion by esophageal squamous cells stimulated with IL-13 and exposed to acid and/or bile salt media, with or without omeprazole.
Results: There was strong correlation between peak eosinophil numbers and peak eotaxin-3-positive epithelial cell numbers in esophageal biopsies. Eotaxin-3 expression decreased significantly with PPIs only in the proximal esophagus. In esophageal cells, exposure to acid-bile salt medium significantly suppressed IL-13-induced eotaxin-3 secretion; omeprazole added to the acid-bile salt medium further suppressed that eotaxin-3 secretion, but not as profoundly as at pH-neutral conditions.
Conclusion: In children with esophageal eosinophilia, PPIs significantly decrease eotaxin-3 expression in the proximal but not the distal esophagus. In esophageal squamous cells, acid and bile salts decrease Th2 cytokine-stimulated eotaxin-3 secretion profoundly, possibly explaining the disparate PPI effects on the proximal and distal esophagus. In the distal esophagus, where acid reflux is greatest, a PPI-induced reduction in acid reflux (an effect that could increase eotaxin-3 secretion induced by Th2 cytokines) might mask the acid-independent, anti-inflammatory PPI effect of decreasing cytokine-stimulated eotaxin-3 secretion.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Straumann A, Kristl J, Conus S, Vassina E, Spichtin HP, et al. (2005) Cytokine expression in healthy and inflamed mucosa: probing the role of eosinophils in the digestive tract. Inflamm Bowel Dis 11: 720–726.
- Straumann A, Bauer M, Fischer B, Blaser K, Simon HU (2001) Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 108: 954–961.
- Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, et al. (2007) IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol 120: 1292–1300.
- Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, et al. (2006) Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 116: 536–547.
- Cheng E, Zhang X, Huo X, Yu C, Zhang Q, et al. (2013) Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 62: 824–832.
- Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, et al.. (2011) Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 128: : 3–20 e26; quiz 21–22.
- DeBrosse CW, Franciosi JP, King EC, Butz BK, Greenberg AB, et al. (2011) Long-term outcomes in pediatric-onset esophageal eosinophilia. J Allergy Clin Immunol 128: 132–138.
- Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, et al. (2003) Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 125: 1660–1669.
- Spechler SJ, Genta RM, Souza RF (2007) Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 102: 1301–1306.
- Kedika RR, Souza RF, Spechler SJ (2009) Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 54: 2312–2317.
- Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, et al. (2005) The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol 509: 201–210.
- Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, et al. (2006) Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res 55: 476–480.
- Zhang X, Cheng E, Huo X, Yu C, Zhang Q, et al. (2012) Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One 7: e50037.
- Huo X, Zhang X, Yu C, Zhang Q, Cheng E, et al. (2013) In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-kappaB and activator protein-1. Gut 63: 1042–1052.
- Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, et al. (2007) Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 133: 1342–1363.
- Zhang HY, Zhang X, Chen X, Thomas D, Hormi-Carver K, et al. (2008) Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol 295: G470–478.
- Cortes JR, Rivas MD, Molina-Infante J, Gonzalez-Nunez MA, Perez GM, et al.. (2009) Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. J Allergy Clin Immunol 124 : 607–610, 610 e601.
- Kauer WK, Peters JH, DeMeester TR, Feussner H, Ireland AP, et al. (1997) Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 122: 874–881.
- Liu T, Zhang X, So CK, Wang S, Wang P, et al. (2007) Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis 28: 488–496.
- Richter JE, Bradley LA, DeMeester TR, Wu WC (1992) Normal 24-hr ambulatory esophageal pH values. Influence of study center, pH electrode, age, and gender. Dig Dis Sci 37: 849–856.
- Vandenplas Y, Goyvaerts H, Helven R, Sacre L (1991) Gastroesophageal reflux, as measured by 24-hour pH monitoring, in 509 healthy infants screened for risk of sudden infant death syndrome. Pediatrics 88: 834–840.
- Hirano I, Richter JE (2007) ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 102: 668–685.
- Molina-Infante J, Rivas MD, Rodriguez GV, Hernandez-Alonso M, Dueñas-Sadornil C, et al.. (2013) SU1828 Remission in Proton Pump Inhibitors-Responsive Esophageal Eosinophilia Correlates With Downregulation of Eotaxin-3 and TH2 Cytokines, Similarly to Eosinophilic Esophagitis After Steroids [abstract]. Gastroenterology 144 (1 Suppl): S484-.
- Frazzoni M, Conigliaro R, Melotti G (2011) Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitis. Aliment Pharmacol Ther 33: 601–606.
- Olsen EA, Brambrink AM (2013) Anesthesia for the young child undergoing ambulatory procedures: current concerns regarding harm to the developing brain. Curr Opin Anaesthesiol 26: 677–684.
- Dranove JE, Horn DS, Davis MA, Kernek KM, Gupta SK (2009) Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 154: 96–100.
- Sayej WN, Patel R, Baker RD, Tron E, Baker SS (2009) Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr 49: 393–399.
- Peterson KA, Thomas KL, Hilden K, Emerson LL, Wills JC, et al. (2010) Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 55: 1313–1319.
- Molina-Infante J, Ferrando-Lamana L, Ripoll C, Hernandez-Alonso M, Mateos JM, et al. (2011) Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 9: 110–117.
- Schroeder S, Capocelli KE, Masterson JC, Harris R, Protheroe C, et al. (2013) Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr 56: 166–172.
- Moawad FJ, Veerappan GR, Dias JA, Baker TP, Maydonovitch CL, et al. (2013) Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 108: 366–372.
- Dellon ES, Speck O, Woodward K, Gebhart JH, Madanick RD, et al. (2013) Clinical and Endoscopic Characteristics do Not Reliably Differentiate PPI-Responsive Esophageal Eosinophilia and Eosinophilic Esophagitis in Patients Undergoing Upper Endoscopy: A Prospective Cohort Study. Am J Gastroenterol 108: 1854–1860.
Source: PubMed